News Flash

US' Kimberly-Clark elects Joseph Romanelli to board of directors

18 Nov '24

1 min read

US' Kimberly-Clark elects Joseph Romanelli to board of directors

Joseph Romanelli. Pic: Merck

Insights

Kimberly-Clark has appointed Joseph Romanelli, president of Human Health International at Merck, to its board of directors, increasing the board size to 13.
Romanelli brings global leadership experience and expertise in science and healthcare.
He has led MSD's international markets since 2022 and previously served as CEO of JiXing Pharmaceuticals.

Kimberly-Clark Corporation has announced that Joseph Romanelli, president of Human Health International for Merck & Co, (MSD) has been elected to its board of directors, effective immediately. In connection with the election, Kimberly-Clark's board size will increase from 12 to 13 directors.

"Joe Romanelli is an outstanding addition to the Kimberly-Clark board of directors," said Mike Hsu, chairman and chief executive officer of Kimberly-Clark. "As we advance our powering care strategy, we will benefit from Romanelli’s global leadership experience and his expertise in using leading-edge science to save and improve lives around the world."

Romanelli has served as president of human health international for MSD, a global healthcare company that develops and manufactures medicines, vaccines, biologic therapies, and animal health products, since 2022. In this role, he oversees MSD's 75-plus markets outside of the US and leads a team of 14,000 colleagues. Prior to joining MSD, Romanelli served as the chief executive officer of JiXing Pharmaceuticals, a China-based biopharmaceutical company. Previously, he served in a variety of strategic and operational roles with increasing responsibility at MSD and Schering-Plough for 25 years.

Fibre2Fashion News Desk (RR)

More Kimberly-Clark Corporation News...